オンコロジー精密医療市場：タイプ別、がん種別、最終用途別-2025-2030年の世界予測

オンコロジー精密医療市場は、2023年に73億4,000万米ドルと評価され、2024年には76億7,000万米ドルに達すると予測され、CAGR 9.10％で成長し、2030年には135億1,000万米ドルに達すると予測されています。

オンコロジー精密医療は、治療効果を最適化するために、ゲノム、バイオマーカー、その他の分子情報を活用し、各患者のがんの特徴に合わせて治療を調整することを指します。プレシジョン・メディシンの必要性は、治療成績の向上、副作用の軽減、ヘルスケア提供の効率化を実現することにあります。その応用範囲は診断、治療モニタリング、治療革新に及び、がんセンター、病院、調査機関に大きな影響を与えています。最終用途の範囲は急速に拡大しており、個別化がんワクチン、標的療法、次世代シーケンス技術などが含まれます。市場に影響を与える主な成長要因としては、ゲノミクスの技術的進歩、がん有病率の増加、有利な政府の取り組み、製薬会社とバイオテクノロジー企業間のパートナーシップの高まりなどが挙げられます。この分野における最近のビジネスチャンスは、予測精度を高めるための人工知能とビッグデータ解析の統合や、アクセス可能性を広げるための費用対効果の高い次世代シーケンス法の開発にあります。また、一般的ながんだけでなく、希少がんや十分な治療を受けていないがん種にまで精密医療の応用を拡大する可能性もあります。

しかし、高度な診断にかかるコストの高さ、データ管理の複雑さ、規制上のハードル、複雑な遺伝子情報を解釈する熟練した専門家の必要性といった課題が、市場の成長に大きな制約を与えています。この分野における技術革新は、強固なバイオインフォマティクス・ソリューションの開発、がん生物学の理解の強化、適応性のある臨床試験デザインの構築に焦点を当てることができます。さらに、テクノロジー企業との提携により、データに基づく洞察が強化され、患者の層別化と個別化治療レジメンが改善される可能性があります。市場は依然として非常にダイナミックであり、競合が新規診断法や治療手法の進歩に拍車をかけています。新たな動向を活用するために、利害関係者は共同研究に投資し、患者中心のアプローチに注力し、政策立案者と積極的に関与して有利な規制の枠組みを促進することで、日常臨床における精密腫瘍学の広範な採用と統合を推進すべきです。

市場力学：急速に進化するオンコロジー精密医療市場の主要市場インサイトを公開

オンコロジー精密医療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界人口におけるがん罹患率の上昇
  • 精密医療を推進する政府の取り組み
  • 精密医療を強化するための遺伝子検査導入の増加
• 市場抑制要因
  • オンコロジー精密医療治療に対する償還の制限
• 市場機会
  • がん治療のための個別化医療を開発するための継続的な研究開発
  • 腫瘍組織およびリキッドバイオプシーにおける臨床次世代シーケンスの進歩
• 市場の課題
  • プレシジョン・オンコロジーを取り巻く複雑な規制の枠組み

ポーターのファイブフォース：オンコロジー精密医療市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：オンコロジー精密医療市場における外部からの影響の把握

外部マクロ環境要因は、オンコロジー精密医療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析オンコロジー精密医療市場における競合情勢の把握

オンコロジー精密医療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックスオンコロジー精密医療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、オンコロジー精密医療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨オンコロジー精密医療市場における成功への道筋を描く

オンコロジー精密医療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界人口におけるがん発症率の上昇
    • 精密医療を推進する政府の取り組み
    • 精密医療を強化するために遺伝子検査の導入を拡大
  • 抑制要因
    • オンコロジー精密医療治療には限定的な払い戻しがあります
  • 機会
    • がん治療のための個別化医療の開発に向けた継続的な研究開発
    • 腫瘍組織および液体生検のための臨床次世代シーケンシングの進歩
  • 課題
    • 精密腫瘍学を取り巻く複雑な規制枠組み
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 オンコロジー精密医療市場：タイプ別

• 細胞・遺伝子治療
• 阻害薬
• モノクローナル抗体

第7章 オンコロジー精密医療市場がんの種類別

• 乳がん
• 子宮頸がん
• 大腸がん
• 肺がん
• 前立腺がん

第8章 オンコロジー精密医療市場：最終用途別

• 病院および診断研究所
• 製薬・バイオテクノロジー企業

第9章 南北アメリカのオンコロジー精密医療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のオンコロジー精密医療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのオンコロジー精密医療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• AbbVie Inc.
• AstraZeneca PLC
• B. J. Madan & Co.
• Bayer AG
• Bristol-Myers Squibb Company
• Cepheid Inc.
• Eli Lilly & Company
• F. Hoffmann-La Roche Ltd
• Genome Medical boasts
• GSK PLC
• IQVIA Inc.
• Laboratory Corporation of America Holding
• llumina, Inc.
• Merck KGaA
• Novartis AG
• OneOme, LLC
• Pfizer Inc.
• Rain Oncology Inc.
• Relay Therapeutics
• Sanofi S.A.
• Strata Oncology, Inc.
• Takeda Pharmaceutical Company Limited
• Thermo Fisher Scientific, Inc.
• Variantyx, Inc.
• Xilis, Inc.

LIST OF FIGURES

• FIGURE 1. ONCOLOGY PRECISION MEDICINE MARKET RESEARCH PROCESS
• FIGURE 2. ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. ONCOLOGY PRECISION MEDICINE MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. ONCOLOGY PRECISION MEDICINE MARKET DYNAMICS
• TABLE 7. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CELL & GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY INHIBITOR DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CERVICAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COLORECTAL CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY LUNG CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PROSTATE CANCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY HOSPITALS & DIAGNOSTIC LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 21. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 22. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 23. AMERICAS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 24. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 25. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 26. ARGENTINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 27. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 28. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 29. BRAZIL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 30. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 31. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 32. CANADA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 33. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 34. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 35. MEXICO ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 36. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 37. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 38. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 39. UNITED STATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 40. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 41. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 42. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 43. ASIA-PACIFIC ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 44. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AUSTRALIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 47. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 48. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 49. CHINA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 50. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 51. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 52. INDIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 53. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 54. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 55. INDONESIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 56. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 57. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 58. JAPAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 59. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 60. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 61. MALAYSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 62. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 63. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 64. PHILIPPINES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 65. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 66. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 67. SINGAPORE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 68. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 69. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 70. SOUTH KOREA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 71. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 72. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 73. TAIWAN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 74. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 75. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 76. THAILAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 77. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 78. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 79. VIETNAM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 80. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 81. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 82. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 83. EUROPE, MIDDLE EAST & AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 84. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 85. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 86. DENMARK ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 87. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 88. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EGYPT ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 90. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 91. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 92. FINLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 93. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 94. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 95. FRANCE ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 96. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 97. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 98. GERMANY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 99. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 100. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 101. ISRAEL ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 102. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 103. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 104. ITALY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 105. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 106. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 107. NETHERLANDS ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 108. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 109. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 110. NIGERIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 111. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 112. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 113. NORWAY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 114. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 115. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 116. POLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 117. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 118. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 119. QATAR ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 120. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 121. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 122. RUSSIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 123. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 124. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 125. SAUDI ARABIA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 126. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 127. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 128. SOUTH AFRICA ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 129. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 130. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 131. SPAIN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 132. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 134. SWEDEN ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 135. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 137. SWITZERLAND ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 138. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 139. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 140. TURKEY ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 141. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 142. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 143. UNITED ARAB EMIRATES ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 144. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 145. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY CANCER TYPE, 2018-2030 (USD MILLION)
• TABLE 146. UNITED KINGDOM ONCOLOGY PRECISION MEDICINE MARKET SIZE, BY END-USE, 2018-2030 (USD MILLION)
• TABLE 147. ONCOLOGY PRECISION MEDICINE MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 148. ONCOLOGY PRECISION MEDICINE MARKET, FPNV POSITIONING MATRIX, 2023

The Oncology Precision Medicine Market was valued at USD 7.34 billion in 2023, expected to reach USD 7.67 billion in 2024, and is projected to grow at a CAGR of 9.10%, to USD 13.51 billion by 2030.

Oncology precision medicine refers to the tailoring of medical treatment to the individual characteristics of each patient's cancer, leveraging genomic, biomarker, and other molecular information to optimize therapeutic efficacy. The necessity of precision medicine arises from its ability to improve treatment outcomes, reduce adverse effects, and enhance the efficiency of healthcare delivery. Its applications span across diagnosis, treatment monitoring, and therapeutic innovation, significantly impacting cancer centers, hospitals, and research institutions. The end-use scope is rapidly expanding to include personalized cancer vaccines, targeted therapies, and next-generation sequencing technologies. Key growth factors influencing the market include technological advancements in genomics, increasing prevalence of cancer, favorable government initiatives, and rising partnerships between pharmaceutical firms and biotech companies. Recent opportunities in this field lie in integrating artificial intelligence and big data analytics to enhance predictive accuracy and developing cost-effective next-generation sequencing methods to widen accessibility. There's also potential in expanding precision medicine applications beyond common cancers into rare and underserved cancer types.

However, challenges such as high costs of advanced diagnostics, complexity in data management, regulatory hurdles, and a need for skilled professionals to interpret complex genetic information pose significant limitations to market growth. Innovation in this sector could focus on developing robust bioinformatics solutions, enhancing the understanding of cancer biology, and creating adaptive clinical trial designs. Furthermore, engaging in collaborations with technology firms could enhance data-driven insights, improving patient stratification and personalized treatment regimens. The market remains highly dynamic, with competition spurring advancements in novel diagnostics and therapeutic methodologies. To capitalize on emerging trends, stakeholders should invest in collaborative research, focus on patient-centric approaches, and actively engage with policymakers to facilitate favorable regulatory frameworks, thus driving broader adoption and integration of precision oncology in routine clinical practice.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Oncology Precision Medicine Market

The Oncology Precision Medicine Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rising incidence of cancer among the global population
  • Government initiatives to promote precision medicine
  • Increasing adoption of genetic testing to enhance precision medicine
• Market Restraints
  • Limited reimbursement available for oncology precision medicine treatment
• Market Opportunities
  • Ongoing R&D to develop personalized medicine to treat cancer
  • Advances in clinical next-generation sequencing for tumor tissue and liquid biopsy
• Market Challenges
  • Complex regulatory framework surrounding precision oncology

Porter's Five Forces: A Strategic Tool for Navigating the Oncology Precision Medicine Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Oncology Precision Medicine Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Oncology Precision Medicine Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Oncology Precision Medicine Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Oncology Precision Medicine Market

A detailed market share analysis in the Oncology Precision Medicine Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Oncology Precision Medicine Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Oncology Precision Medicine Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Oncology Precision Medicine Market

A strategic analysis of the Oncology Precision Medicine Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Oncology Precision Medicine Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., AstraZeneca PLC, B. J. Madan & Co., Bayer AG, Bristol-Myers Squibb Company, Cepheid Inc., Eli Lilly & Company, F. Hoffmann-La Roche Ltd, Genome Medical boasts, GSK PLC, IQVIA Inc., Laboratory Corporation of America Holding, llumina, Inc., Merck KGaA, Novartis AG, OneOme, LLC, Pfizer Inc., Rain Oncology Inc., Relay Therapeutics, Sanofi S.A., Strata Oncology, Inc., Takeda Pharmaceutical Company Limited, Thermo Fisher Scientific, Inc., Variantyx, Inc., and Xilis, Inc..

Market Segmentation & Coverage

This research report categorizes the Oncology Precision Medicine Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Cell & Gene Therapy, Inhibitor drugs, and Monoclonal Antibodies.
• Based on Cancer Type, market is studied across Breast Cancer, Cervical Cancer, Colorectal Cancer, Lung Cancer, and Prostate Cancer.
• Based on End-use, market is studied across Hospitals & Diagnostic Laboratories and Pharmaceutical & Biotechnology Companies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rising incidence of cancer among the global population
    • 5.1.1.2. Government initiatives to promote precision medicine
    • 5.1.1.3. Increasing adoption of genetic testing to enhance precision medicine
  • 5.1.2. Restraints
    • 5.1.2.1. Limited reimbursement available for oncology precision medicine treatment
  • 5.1.3. Opportunities
    • 5.1.3.1. Ongoing R&D to develop personalized medicine to treat cancer
    • 5.1.3.2. Advances in clinical next-generation sequencing for tumor tissue and liquid biopsy
  • 5.1.4. Challenges
    • 5.1.4.1. Complex regulatory framework surrounding precision oncology
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Oncology Precision Medicine Market, by Type

• 6.1. Introduction
• 6.2. Cell & Gene Therapy
• 6.3. Inhibitor drugs
• 6.4. Monoclonal Antibodies

7. Oncology Precision Medicine Market, by Cancer Type

• 7.1. Introduction
• 7.2. Breast Cancer
• 7.3. Cervical Cancer
• 7.4. Colorectal Cancer
• 7.5. Lung Cancer
• 7.6. Prostate Cancer

8. Oncology Precision Medicine Market, by End-use

• 8.1. Introduction
• 8.2. Hospitals & Diagnostic Laboratories
• 8.3. Pharmaceutical & Biotechnology Companies

9. Americas Oncology Precision Medicine Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Oncology Precision Medicine Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Oncology Precision Medicine Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. AbbVie Inc.
• 2. AstraZeneca PLC
• 3. B. J. Madan & Co.
• 4. Bayer AG
• 5. Bristol-Myers Squibb Company
• 6. Cepheid Inc.
• 7. Eli Lilly & Company
• 8. F. Hoffmann-La Roche Ltd
• 9. Genome Medical boasts
• 10. GSK PLC
• 11. IQVIA Inc.
• 12. Laboratory Corporation of America Holding
• 13. llumina, Inc.
• 14. Merck KGaA
• 15. Novartis AG
• 16. OneOme, LLC
• 17. Pfizer Inc.
• 18. Rain Oncology Inc.
• 19. Relay Therapeutics
• 20. Sanofi S.A.
• 21. Strata Oncology, Inc.
• 22. Takeda Pharmaceutical Company Limited
• 23. Thermo Fisher Scientific, Inc.
• 24. Variantyx, Inc.
• 25. Xilis, Inc.